Impact of the COVID-19 Pandemic on Drug Use and Monitoring of Cancer Patients (ONCORAL-Covid)

Civil Hospices of Lyon

Status: Completed

Conditions: Cancer

Treatments: Other: Directive Interview

Study type: Observational

Funder types: Other

Identifiers

NCT05069662

69HCL21_0163

Details and patient eligibility

About

The COVID-19 pandemic has profoundly changed the organisation of care. Teleconsultation has replaced hospital medical consultations in order to reduce the risk of patient exposure to the virus.

Within the framework of the Oncoral multidisciplinary outpatient / hospital program of follow-up, carried out by the Hospices Civils de Lyon for ambulatory patients treated with oral anticancer drugs, interviews with the pharmacist and/or nurse, which were previously organised face-to-face, have been replaced by telephone interviews, ensuring continuity of follow-up for patients without having to come to the hospital.

This study focuses on a telephone survey to describe the impact of the COVID-19 pandemic health crisis on the drug exposure of cancer patients followed in the Oncoral program, their treatment management, their perception of teleconsultation and their IT resources for remote monitoring.

Enrollment: 120 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Adult patients aged 18 and over
• Ambulatory patients treated with oral anticancer drugs and benefiting from the ONCORAL multidisciplinary outpatient / hospital program
• Having benefited from a remote monitoring between March 16, 2020 and May 11, 2020 (the COVID-19 pandemic-related containment period)
• Patients who do not object to participating in the survey and to the use of the data collected

Exclusion criteria

• Patients who do not speak French
• Patients living in an institution
• Patients protected by law
• Patients included in a drug clinical trial
• Patients refusing to participate in the survey and / or not responding to the 2 telephone calls requesting their participation and / or not responding to any of these calls
• Patients choosing to stop the interview and no longer answering to the questions asked

Trial design

120 participants in 1 patient group

Patients treated with oral anticancer drugs

Description:

Patients treated with oral anticancer drugs followed in the Oncoral program

Treatment:

Other: Directive Interview